Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Next-Generation Sequencing in Medicine (Upcoming)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • Gut-Brain Axis (Jul 2021)
    • Tumor Microenvironment (Mar 2021)
    • 100th Anniversary of Insulin's Discovery (Jan 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine
Davide Corti, … , Kanta Subbarao, Antonio Lanzavecchia
Davide Corti, … , Kanta Subbarao, Antonio Lanzavecchia
Published April 12, 2010
Citation Information: J Clin Invest. 2010;120(5):1663-1673. https://doi.org/10.1172/JCI41902.
View: Text | PDF
Research Article Infectious disease

Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine

  • Text
  • PDF
Abstract

The target of neutralizing antibodies that protect against influenza virus infection is the viral protein HA. Genetic and antigenic variation in HA has been used to classify influenza viruses into subtypes (H1–H16). The neutralizing antibody response to influenza virus is thought to be specific for a few antigenically related isolates within a given subtype. However, while heterosubtypic antibodies capable of neutralizing multiple influenza virus subtypes have been recently isolated from phage display libraries, it is not known whether such antibodies are produced in the course of an immune response to influenza virus infection or vaccine. Here we report that, following vaccination with seasonal influenza vaccine containing H1 and H3 influenza virus subtypes, some individuals produce antibodies that cross-react with H5 HA. By immortalizing IgG-expressing B cells from 4 individuals, we isolated 20 heterosubtypic mAbs that bound and neutralized viruses belonging to several HA subtypes (H1, H2, H5, H6, and H9), including the pandemic A/California/07/09 H1N1 isolate. The mAbs used different VH genes and carried a high frequency of somatic mutations. With the exception of a mAb that bound to the HA globular head, all heterosubtypic mAbs bound to acid-sensitive epitopes in the HA stem region. Four mAbs were evaluated in vivo and protected mice from challenge with influenza viruses representative of different subtypes. These findings reveal that seasonal influenza vaccination can induce polyclonal heterosubtypic neutralizing antibodies that cross-react with the swine-origin pandemic H1N1 influenza virus and with the highly pathogenic H5N1 virus.

Authors

Davide Corti, Amorsolo L. Suguitan Jr., Debora Pinna, Chiara Silacci, Blanca M. Fernandez-Rodriguez, Fabrizia Vanzetta, Celia Santos, Catherine J. Luke, Fernando J. Torres-Velez, Nigel J. Temperton, Robin A. Weiss, Federica Sallusto, Kanta Subbarao, Antonio Lanzavecchia

×

Figure 2

Detection of heterosubtypic antibodies in plasma samples following seasonal vaccination.

Options: View larger image (or click on image) Download as PowerPoint
Detection of heterosubtypic antibodies in plasma samples following seaso...
ELISA plates were coated with vaccine or H5 HAs and incubated with serial plasma dilutions, followed by biotinylated FE17 or FE43 mAbs, which were then detected using enzyme-conjugated streptavidin. Shown is the reciprocal plasma dilution that blocks 80% binding (BD80) of heterosubtypic mAbs FE17 and FE43 to homologous HA (A) or heterologous H5 HA (B). Each symbol represents a different individual from Figure 1, A and C. Lines indicate geometric mean values.

Copyright © 2022 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts